[1] [1] A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray, M. J. Thun, “Cancer statistics, 2008,” CA Cancer J. Clin. 58, 71–96 (2008).

[2] [2] R. A. Smith, V. Cokkinides, H. J. Eyre, “American cancer society guidelines for the early detection of cancer, 2006,” CA Cancer J. Clin. 56, 11–25 (2006).

[3] [3] A. Rolle, U. Pachmann, B. Willen, K. Pachmann, “Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC is a predictor for relapse: A preliminary report,” World J. Surg. Oncol. 3, 18 (2005).

[4] [4] V. Zieglschmid, C. Hollmann, O. Bocher, “Detection of disseminated tumor cells in peripheral blood,” Crit. Rev. Clin. Lab. Sci. 42, 155–196 (2005).

[5] [5] H. J. Kahn, A. Presta, L. Y. Yang, J. Blondal, M. Trudeau, L. Lickley, C. Holloway, D. R. McCready, D. Maclean, A. Marks, “Enumeration of circulating tumor cells in the blood of breast cancer patients after filtration enrichment: Correlation with disease stage,” Breast Cancer Res. Treat. 86, 237–247 (2004).

[6] [6] R.T.Krivacic,A. Ladanyi,D. N. Curry,H. B. Hsieh, P. Kuhn, D. E. Bergsrud, J. F. Kepros, T. Barbera, M. Y. Ho, L. B. Chen, “A rare-cell detector for cancer,” Proc. Nat. Acad. Sci. U. S. A. 101, 10501– 10504 (2004).

[7] [7] E. Racila, D. Euhus, A. J. Weiss, C. Rao, J. McConnell, L. Terstappen, J. W. Uhr, “Detection and characterization of carcinoma cells in the blood,” Proc. Natl. Acad. Sci. U. S. A. 95, 4589– 4594 (1998).

[8] [8] S. Nagrath, L. V. Sequist, S. Maheswaran, D. W. Bell, D. Irimia, L. Ulkus et al., “Isolation of rare circulating tumour cells in cancer patients by microchip technology,” Nature 450, 1235–1239 (2007).

[9] [9] L. Huang, S. J. Maerkl, O. J. Martin, “Integration of plasmonic trapping in a microfluidic environment,” Opt. Express 17, 6018–6024 (2009).

[10] [10] L. Huang,W. Zhang, S. Maerkl, O. J.Martin, “Plasmonic trapping for nanoscale analysis in lab-on-thechip applications,” Frontiers in Optics, Paper FME3 (2008).

[11] [11] K. Narasimhan, Z. Changqing, M. Choolani, “Ovarian cancer proteomics: Many technologies one goal,” Prot. Clin. Appl. 2, 195–218 (2008).

[12] [12] O. H. J. Szolar, S. Stranner, I. Zinoecker, G. C. Mudde, G. Himmler, G. Waxenecker, A. Nechansky, “Qualification and application of a surface plasmon resonance-based assay for monitoring potential HAHA responses induced after passive administration of a humanized anti Lewis-Y antibody,” J. Pharm. Biomed. Anal. 41, 1347–1353 (2006).

[13] [13] D. Huang, E. A. Swanson, C. P. Lin, J. S. Schuman, W. G. Stinson, W. Chang, M. R. Hee, T. Flotte, K. Gregory, C. A. Puliafito, “Optical coherence tomography,” Science 254, 1178–1181 (1991).

[14] [14] Z. Ding, Y. Zhao, H. Ren, J. Nelson, Z. Chen, “Realtime phase-resolved optical coherence tomography and optical Doppler tomography,” Opt. Express 10, 236–245 (2002).

[15] [15] J. Meng, Z. Ding, Y. Yang, Z. Guo, “Study on cerebral microcirculation by Optical Doppler Tomography,” Sci. Chin. Ser. G Phys. Mech. Astron. 51, 1883–1891 (2008).

[16] [16] A. F. Fercher, W. Drexler, C. K. Hitzenberger, T. Lasser, “Optical coherence tomographyprinciples and applications,” Rep. Prog. Phys. 66, 239–303 (2003).

[17] [17] K. Wang, Z. Ding, T. Wu, C. Wang, J. Meng, M. Chen, L. Xu, “Development of a non-uniform discrete Fourier transform based high speed spectral domain optical coherence tomography system,” Opt. Express 17, 12121–12131 (2009).